WINDOSR, ONTARIO – April 23rd, 2015
The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known Biotech stocks would like to highlight several oncology (or cancer) focused biotech stocks making news and subsequent market moves.
This week has set the tone for all of 2015 with the announcement by Juno Therapeutics’ (NASDAQ: JUNO) phase 1 results for its CAR-T cell therapy JCAR017. Basically, 20 out of 22 young children with advanced stage Leukemia went into full remission when treated with Juno’s therapy—these are patients that were previously having absolutely no response to traditional treatments such as chemotherapy. More compelling than curing 92% of a test group of terminally ill children, is the fact that new drugs, drugs in phase 1, are only supposed to be tested for safety, to see if the drug will harm the patient. Results for effectiveness aren’t typically expected until phase 2. This is what is so compelling in this new white-hot sector known as “Immunotherapy.” Juno’s stock chart looks to have found support in the $55 range after a somewhat artificial sell-off stemming from the news of another unrelated company.
Although Immunotherapy is the hottest sub-sector of healthcare, most of the positive news has surrounded the Companies treating blood cancers like Juno Therapeutics Inc. (NASDAQ: JUNO) and Kite Pharma Inc. (NASDAQ: KITE) — Some setbacks have occurred in the solid tumor treatment field (*cough* Novartis). For obvious reasons drug companies have a huge interest in treating actual tumors as they represent the majority of most lethal cancers and hold the largest profit potential for drugs, treatments and therapies.
One company with strong promise in the area of solid tumor treatment is entering its pre-clinical animal studies, which, if successful, could allow the company to enter the exciting (this is usually when stocks move) FDA clinical trials. Propanc Health Group Inc. (OTC: PPCH) recently announced raising the capital to start these animal studies which are now underway. Propanc (OTC: PPCH) is working on a “proenzyme,” that is a naturally occurring compound found in the human pancreas. The Company and its research team feel that this proenzyme could prove as an effective “Cell Differentiating Targeted Therapy.” In more simplistic terms, the compound is intended to interact with specific proteins on tumor cells to stop the abnormal cells from multiplying uncontrollably and return to a normal state. The other thesis is that this proenzyme (PRP) will help to prevent metastasis, or the horrible omen of normal sells mutating into cancer, the earliest stages of this disease. The company’s stock has been on a wild ride of late, but traders and chart readers are speculating that if support holds at ~$0.03, and prices move past the previous high of $0.10, the stock could move towards the next resistance at roughly $0.20—or roughly 500% higher than current prices.
Two other very hot stocks that look to be trending bullish are Advaxis Inc. (NASDAQ: ADXS) and Geron Corporation (NASDAQ: GERN).
Geron (NASDAQ: GERN) is a clinical stage biopharmaceutical company developing a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies—or tumors that affect the blood/ bone and lymph systems. NASDAQ: GERN is an under-the-radar contrarian play that looks to be just getting started; like what happens with most small cap stocks, GERN was recently upgraded by a few analysts (Barrons, Zacks, and Oppenheimer) and didn’t really get the market love it deserved. This stock looks like it may cross the $5.00 barrier, out of penny stock land, and make its way to the next historical resistance of $10.00. During the tech bubble of the late 90’s this ticker hit $70.00, so who knows where it will end up. The Wealthy Biotech Trader feels the current secular bull market in biotech is just getting started as baby boomers age and heath care spending goes parabolic. Retail traders are just now starting to discover these exciting Biotech plays.
Advaxis Inc. (NASDAQ: ADXS) is a Wall Street darling that’s chart has recently gone parabolic—the shares have literally gone from $2.50 to almost $25.00. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack. ADXS is one of the few success stories from the OTC exchange by which the Company up-listed to the NASDAQ, a very seldom occurrence– although most CEO’s on the OTC talk about it incessantly. Traders may look for this name to retrace a bit of the recent move before entering, but with this Company’s large pipeline and big pharma partnerships, ADXS may be multi-billion dollar stock in the near future.
2015 is shaping up to be a stellar year for oncology-focused Biotech stocks and The Wealthy Biotech Trader will be watching the key players very closely. Make sure to add Propanc Health Group (OTC: PPCH) to your trading radars to stay up-to-date with Company news, especially the animal trials currently underway which could be a near-term catalyst.
The Wealthy Biotech Trader is researching several new trade ideas which have the makings for large market moves. Active traders are urged to follow our parent outlet, The Wealthy Venture Capitalist on social media to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through our Twitter and Facebook accounts, as well as newswire.
TO GET BREAKING NEWS FROM US:
Follow us on twitter: @Wealthy_VC
Like us on Facebook: www.facebook.com/WealthyVC
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage.
Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.